Clinical Trial Update: Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2) [Phase 2]

View source ↗

Summary

Phase 2 trial ONYX-2 evaluating YM150, a Factor Xa inhibitor by Astellas, for prevention of venous thromboembolism after hip replacement; the study status is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• YM150

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Thromboembolism | Phase 2 | Status: COMPLETED